Antiviral Treatment for Chronic Hepatitis B in Renal Transplant Patients

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Mar 3

PMID 25729474

Citations 7

Authors

Ezequiel Ridruejo

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B infection is frequent in renal transplant patients. It negatively impacts long term outcomes reducing graft and patient survival. Current guidelines clearly define who needs treatment, when to start, what is the first line therapy, how to monitor treatment response, when to stop, and how patients must be controlled for its safety. There is some data showing a favorable safety and efficacy profile of nucleos(t)ide analogue (NUC) treatment in the renal transplant setting. Entecavir, a drug without major signs of nephrotoxicity, appears to be the first option for NUC naïve patients and tenofovir remains the preferred choice for patients with previous resistance to lamivudine or any other NUC. Renal transplant recipients under antiHBV therapy should be monitored for its efficacy against HBV but also for its safety with a close renal monitoring. Studies including a large number of patients with long term treatment and follow up are still needed to better demonstrate the safety and efficacy of newer NUCs in this population.

Citing Articles

INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Arora A, Kumar A, Prasad N, Duseja A, Acharya S, Agarwal S J Clin Exp Hepatol. 2021; 11(3):354-386.

PMID: 33994718 PMC: 8103529. DOI: 10.1016/j.jceh.2020.09.005.

Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections.

Pradhan D, Biswasroy P, Goyal A, Ghosh G, Rath G AAPS PharmSciTech. 2021; 22(1):47.

PMID: 33447909 PMC: 7808403. DOI: 10.1208/s12249-020-01908-5.

INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.

Arora A, Anand A, Kumar A, Singh S, Aggarwal R, Dhiman R J Clin Exp Hepatol. 2018; 8(4):403-431.

PMID: 30568345 PMC: 6286881. DOI: 10.1016/j.jceh.2018.06.010.

Hepatitis B Virus Infection and Organ Transplantation.

Ayoub W, Martin P, Bhamidimarri K Gastroenterol Hepatol (N Y). 2018; 14(1):33-40.

PMID: 29491759 PMC: 5824593.

Tenofovir and kidney transplantation: case report.

Battaglia Y, Cojocaru E, Forcellini S, Russo L, Russo D Clin Nephrol Case Stud. 2017; 4:18-23.

PMID: 29043137 PMC: 5438008. DOI: 10.5414/CNCS108929.

References

Shu K, Ho H, Wen M, Wu M, Chen C, Cheng C . Changing pattern of mortality in renal transplant recipients: a single-center, 30-year experience. Transplant Proc. 2014; 46(2):442-4. DOI: 10.1016/j.transproceed.2013.11.032. View

Fontana R . Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49(5 Suppl):S185-95. DOI: 10.1002/hep.22885. View

Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P . Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011; 55(6):1235-40. DOI: 10.1016/j.jhep.2011.03.030. View

Burdick R, Bragg-Gresham J, Woods J, Hedderwick S, Kurokawa K, Combe C . Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003; 63(6):2222-9. DOI: 10.1046/j.1523-1755.2003.00017.x. View

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

Gane E, Pilmore H . Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74(4):427-37. DOI: 10.1097/00007890-200208270-00001. View

Fabrizi F, MARTIN P, Dixit V, Kanwal F, Dulai G . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5(12):2913-21. DOI: 10.1111/j.1600-6143.2005.01113.x. View

Ahmad A, Hasan F, Abdeen S, Sheikh M, Kodaj J, Nampoory M . Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol. 2004; 15(3):257-60. DOI: 10.1097/01.rvi.0000109403.52762.c4. View

Hu T, Tsai M, Chien Y, Chen Y, Chen T, Lin M . A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. Antivir Ther. 2012; 17(4):745-53. DOI: 10.3851/IMP2097. View

10.

Kim H, Kim E, Yu Y, Kim G, Jeong J, Byeon J . Comparison of clinical outcomes in hepatitis B virus-positive kidney transplant recipients with or without pretransplantation antiviral therapy. Transplant Proc. 2013; 45(4):1374-8. DOI: 10.1016/j.transproceed.2013.01.088. View

11.

Park K, Han D, Park J, Park J, Park S . Long-term outcome of Hepatitis B-positive renal allograft recipients after development of antiviral treatment. Clin Nephrol. 2012; 78(5):391-8. DOI: 10.5414/CN107565. View

12.

Garcia A, Mazuecos A, Gonzalez P, Diaz F, Garcia T, Ceballos M . Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc. 2005; 37(3):1462-3. DOI: 10.1016/j.transproceed.2005.02.010. View

13.

Manolakopoulos S, Striki A, Deutsch M, Mela M, Ketikoglou I, Tzourmakliotis D . Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int. 2011; 31(10):1525-32. DOI: 10.1111/j.1478-3231.2011.02616.x. View

14.

Kasiske B, Zeier M, Chapman J, Craig J, Ekberg H, Garvey C . KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2009; 77(4):299-311. DOI: 10.1038/ki.2009.377. View

15.

Pipili C, Cholongitas E, Papatheodoridis G . Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2013; 39(1):35-46. DOI: 10.1111/apt.12538. View

16.

Chan T, Fang G, Tang C, Cheng I, Lai K, Ho S . Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002; 36(5):1246-52. DOI: 10.1053/jhep.2002.36156. View

17.

Barclay S, Pol S, Mutimer D, Benhamou Y, Mills P, Hayes P . The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol. 2008; 41(4):243-54. DOI: 10.1016/j.jcv.2007.11.017. View

18.

Hu T, Tsai M, Chen Y, Chien Y, Hung C, Chen T . The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011; 6(2):449-56. DOI: 10.1007/s12072-011-9295-6. View

19.

Kanaan N, Kabamba B, Marechal C, Pirson Y, Beguin C, Goffin E . Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol. 2012; 55(3):233-8. DOI: 10.1016/j.jcv.2012.07.015. View

20.

de Silva H, Dassanayake A, Manamperi A, De Silva A . Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc. 2006; 38(9):3118-20. DOI: 10.1016/j.transproceed.2006.08.186. View